The reported statements, read against the company's own industry.
Financials view
Market Capitalization
622.22MGBP
827.53M · vs all stocks (USD)
Updated Oct 25, 2026
Revenue (TTM)
175.36MGBP
233.23M · vs all stocks (USD)
Updated Oct 25, 2026
Profit Margin
-23.23%
vs Biotechnology peers
Updated Oct 25, 2026
Beta
1.11x
vs all stocks
Updated Oct 25, 2026
52-Week Change
-17.10%
vs all stocks
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Market Capitalization
622.22MGBP
827.53M · vs all stocks (USD)
Updated Oct 25, 2026
Enterprise Value
705.50MGBP
938.29M · vs all stocks (USD)
Updated Oct 25, 2026
Forward P/E
-70.30x
vs Biotechnology peers
Updated Oct 25, 2026
Price to Sales (TTM)
3.55x
vs Biotechnology peers
Updated Oct 25, 2026
Price to Book (MRQ)
10.71x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to Revenue
4.02x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to EBITDA
-31.05x
vs Biotechnology peers
Updated Oct 25, 2026
Profit Margin
-23.23%
vs Biotechnology peers
Updated Oct 25, 2026
Operating Margin
-26.85%
vs Biotechnology peers
Updated Oct 25, 2026
Return on Assets (TTM)
-7.03%
vs Biotechnology peers
Updated Oct 25, 2026
Return on Equity (TTM)
-89.69%
vs Biotechnology peers
Updated Oct 25, 2026
Revenue (TTM)
175.36MGBP
233.23M · vs all stocks (USD)
Updated Oct 25, 2026
Revenue per Share (TTM)
1.47GBPUpdated Oct 25, 2026
Quarterly Revenue Growth
9.00%
vs Biotechnology peers
Updated Oct 25, 2026
Gross Profit (TTM)
63.46MGBP
84.40M · vs all stocks (USD)
Updated Oct 25, 2026
EBITDA (TTM)
-22.72MGBP
-30.22M · vs all stocks (USD)
Updated Oct 25, 2026
Net Income (TTM)
-40.73MGBP
-54.17M · vs all stocks (USD)
Updated Oct 25, 2026
Operating Cash Flow (TTM)
-20.56MGBP
-27.34M · vs all stocks (USD)
Updated Oct 25, 2026
Levered Free Cash Flow (TTM)
-25.92MGBP
-34.48M · vs all stocks (USD)
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Trailing Annual Dividend Rate
0.00GBPUpdated Oct 25, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 25, 2026
Minority Interest (Equity)
0.00GBPFY2025 · Dec 31, 2025
Revenue
168.74MGBPFY2025 · Dec 31, 2025
Cost of Goods Sold
102.76MGBPFY2025 · Dec 31, 2025
Gross Profit
65.98MGBPFY2025 · Dec 31, 2025
Operating Income
-32.96MGBP
-43.83M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-31.94MGBPFY2025 · Dec 31, 2025
Income Tax Expense
-1.29MGBPFY2025 · Dec 31, 2025
Net Income
-30.64MGBPFY2025 · Dec 31, 2025
EBIT
-17.43MGBPFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-7.37MGBPFY2025 · Dec 31, 2025
Research & Development
5.06MGBPFY2025 · Dec 31, 2025
Selling, General & Administrative
36.76MGBPFY2025 · Dec 31, 2025
Other Operating Expenses
57.70MGBPFY2025 · Dec 31, 2025
Non-operating Interest Income
5.18MGBPFY2025 · Dec 31, 2025
Non-operating Interest Expense
14.50MGBPFY2025 · Dec 31, 2025
EPS (Basic)
-0.2692GBPFY2025 · Dec 31, 2025
EPS (Diluted)
-0.2692GBPFY2025 · Dec 31, 2025
Basic Shares Outstanding
111.92MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
111.92MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-31.94MGBPFY2025 · Dec 31, 2025
Minority Interests (P&L)
517.00KGBPFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00GBPFY2025 · Dec 31, 2025
Operating Cash Flow
-33.05MGBPFY2025 · Dec 31, 2025
Free Cash Flow
-37.81MGBPFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
96.88MGBPFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-31.94MGBPFY2025 · Dec 31, 2025
Stock-based Compensation
4.68MGBPFY2025 · Dec 31, 2025
Other Non-cash Items
-465.00KGBPFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-21.66MGBPFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
16.33MGBPFY2025 · Dec 31, 2025
Capital Expenditures
-4.76MGBPFY2025 · Dec 31, 2025
Net Acquisitions
-3.34MGBPFY2025 · Dec 31, 2025
Net Investing Cash Flow
-8.10MGBPFY2025 · Dec 31, 2025
Long-term Debt Issuance
41.95MGBPFY2025 · Dec 31, 2025
Long-term Debt Payments
-38.77MGBPFY2025 · Dec 31, 2025
Other Financing Charges
-2.00MGBPFY2025 · Dec 31, 2025
Net Financing Cash Flow
59.24MGBPFY2025 · Dec 31, 2025
Shares Outstanding
120.75MSharesUpdated Oct 25, 2026
Float Shares
60.76MSharesUpdated Oct 25, 2026
% Held by Insiders
20.57%
vs all stocks
Updated Oct 25, 2026
% Held by Institutions
64.84%
vs all stocks
Updated Oct 25, 2026
Total Cash (MRQ)
75.28MGBP
100.12M · vs all stocks (USD)
Updated Oct 25, 2026
Total Cash per Share (MRQ)
0.6220GBPUpdated Oct 25, 2026
Total Debt (MRQ)
158.64MGBP
210.99M · vs all stocks (USD)
Updated Oct 25, 2026
Total Debt to Equity (MRQ)
2.73x
vs Biotechnology peers
Updated Oct 25, 2026
Current Ratio (MRQ)
2.21x
vs Biotechnology peers
Updated Oct 25, 2026
Book Value per Share (MRQ)
0.4800GBPUpdated Oct 25, 2026
Total Assets
325.72MGBP
433.20M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
185.65MGBPFY2025 · Dec 31, 2025
Total Liabilities
234.37MGBPFY2025 · Dec 31, 2025
Total Non-current Assets
140.07MGBPFY2025 · Dec 31, 2025
Total Non-current Liabilities
150.15MGBPFY2025 · Dec 31, 2025
Total Current Liabilities
84.22MGBPFY2025 · Dec 31, 2025
Cash
96.88MGBPFY2025 · Dec 31, 2025
Cash & Cash Equivalents
96.88MGBPFY2025 · Dec 31, 2025
Accounts Receivable
22.69MGBPFY2025 · Dec 31, 2025
Inventory
17.33MGBPFY2025 · Dec 31, 2025
Accounts Payable
14.21MGBPFY2025 · Dec 31, 2025
Short-term Debt
6.06MGBPFY2025 · Dec 31, 2025
Long-term Debt
142.07MGBPFY2025 · Dec 31, 2025
Common Stock (Book)
60.38MGBPFY2025 · Dec 31, 2025
Retained Earnings
-422.35MGBPFY2025 · Dec 31, 2025
Total Shareholders' Equity
91.35MGBP
121.49M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
420.00GBXUpdated Oct 25, 2026
52-Week High
962.00GBXUpdated Oct 25, 2026
52-Week Change
-17.10%
vs all stocks
Updated Oct 25, 2026
Beta
1.11x
vs all stocks
Updated Oct 25, 2026
50-Day MA
494.68GBXUpdated Oct 25, 2026
200-Day MA
605.92GBXUpdated Oct 25, 2026
Avg 10-Day Volume
220.82KSharesUpdated Oct 25, 2026
Avg 30-Day Volume
491.30KSharesUpdated Oct 25, 2026
Diluted EPS (TTM)
-0.3200GBPUpdated Oct 25, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 2.73×, higher than 95% of its Biotechnology peers (median 0.09×)Significant